BB Biotech AG

SWX:BION Stock Report

Market Cap: CHF 2.8b

BB Biotech Valuation

Is BION undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BION when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: BION (CHF50.9) is trading below our estimate of future cash flow value (CHF75.03)

Significantly Below Future Cash Flow Value: BION is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BION?

Key metric: As BION is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BION. This is calculated by dividing BION's market cap by their current earnings.
What is BION's PE Ratio?
PE Ratio2.1x
EarningsCHF 1.35b
Market CapCHF 2.81b

Price to Earnings Ratio vs Peers

How does BION's PE Ratio compare to its peers?

Insufficient data to calculate this valuation analysis check
The above table shows the PE ratio for BION vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Averagen/a
BION BB Biotech
2.1x-110.33%CHF 2.8b

Price-To-Earnings vs Peers: Insufficient data to calculate BION's Price-To-Earnings Ratio vs. peers for valuation analysis.

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does BION's PE Ratio compare vs other companies in the European Capital Markets Industry?

18 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.13.8x10.8%
BION BB Biotech
 2.1x-110.33%US$3.46b
BION 2.1xIndustry Avg. 13.8xNo. of Companies46PE01224364860+
18 CompaniesEstimated GrowthMarket Cap
Industry Avg.13.8x10.8%
BION BB Biotech
 2.1x-110.33%US$3.46b
No more companies

Price-To-Earnings vs Industry: BION is good value based on its Price-To-Earnings Ratio (2.1x) compared to the European Capital Markets industry average (13.8x).

Price to Earnings Ratio vs Fair Ratio

What is BION's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BION PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio2.1x
Fair PE Ratio2.1x

Price-To-Earnings vs Fair Ratio: BION is good value based on its Price-To-Earnings Ratio (2.1x) compared to the estimated Fair Price-To-Earnings Ratio (2.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BION forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 50.90
CHF 69.00
+35.56%
5.80%CHF 73.00CHF 65.00n/a2
Jul ’27CHF 49.10
CHF 69.00
+40.53%
5.80%CHF 73.00CHF 65.00n/a2
Jun ’27CHF 43.10
CHF 69.00
+60.09%
5.80%CHF 73.00CHF 65.00n/a2
May ’27CHF 44.15
CHF 69.00
+56.29%
5.80%CHF 73.00CHF 65.00n/a2
Apr ’27CHF 44.40
CHF 69.00
+55.41%
5.80%CHF 73.00CHF 65.00n/a2
Feb ’27CHF 46.35
CHF 56.85
+22.65%
16.09%CHF 66.00CHF 47.70n/a2
Sep ’26CHF 32.35
CHF 53.85
+66.46%
11.42%CHF 60.00CHF 47.70n/a2
Aug ’26CHF 33.30
CHF 53.85
+61.71%
11.42%CHF 60.00CHF 47.70CHF 51.102
Jul ’26CHF 29.80
CHF 53.85
+80.70%
11.42%CHF 60.00CHF 47.70CHF 49.102
Jun ’26CHF 29.35
CHF 53.85
+83.48%
11.42%CHF 60.00CHF 47.70CHF 43.102
May ’26CHF 29.55
CHF 53.85
+82.23%
11.42%CHF 60.00CHF 47.70CHF 44.152
Apr ’26CHF 30.35
CHF 53.85
+77.43%
11.42%CHF 60.00CHF 47.70CHF 44.402
Mar ’26CHF 37.00
CHF 53.85
+45.54%
11.42%CHF 60.00CHF 47.70CHF 47.102
Feb ’26CHF 40.65
CHF 55.85
+37.39%
14.59%CHF 64.00CHF 47.70CHF 46.352
Jan ’26CHF 35.40
CHF 55.85
+57.77%
14.59%CHF 64.00CHF 47.70CHF 44.952
Dec ’25CHF 37.35
CHF 55.85
+49.53%
14.59%CHF 64.00CHF 47.70CHF 44.352
Nov ’25CHF 37.10
CHF 55.85
+50.54%
14.59%CHF 64.00CHF 47.70CHF 41.102
Oct ’25CHF 36.10
CHF 55.85
+54.71%
14.59%CHF 64.00CHF 47.70CHF 36.952
Sep ’25CHF 38.95
CHF 55.85
+43.39%
14.59%CHF 64.00CHF 47.70CHF 32.352
CHF 69
Fair Value
26.2% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/04 09:42
End of Day Share Price 2026/08/03 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BB Biotech AG is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rene RückertBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research
Falko FriedrichsDeutsche Bank